Avacta Revenue and Competitors
Estimated Revenue & Valuation
- Avacta's estimated annual revenue is currently $57.4M per year.
- Avacta's estimated revenue per employee is $155,000
Employee Data
- Avacta has 370 Employees.
Avacta's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Executive | Reveal Email/Phone |
2 | Marketing Officer | Reveal Email/Phone |
3 | VP, Head Biology | Reveal Email/Phone |
4 | VP Chemistry | Reveal Email/Phone |
5 | Head QA/ RA | Reveal Email/Phone |
6 | Chief Commercial Officer, Diagnostics | Reveal Email/Phone |
7 | Group Communications Director | Reveal Email/Phone |
8 | Senior Clinical Trial Manager | Reveal Email/Phone |
9 | Office Manager / Executive Assistant to CDO & CSO | Reveal Email/Phone |
10 | Quality Systems Manager | Reveal Email/Phone |
Avacta Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.4M | 35 | -12% | N/A | N/A |
#2 | $16.3M | 105 | 4% | N/A | N/A |
#3 | $107.2M | 494 | 25% | $292M | N/A |
#4 | $2.6M | 830 | 30% | $631.7M | N/A |
#5 | $18.1M | 117 | -8% | $81M | N/A |
#6 | $1.2M | 271 | 12% | $440M | N/A |
#7 | $54.6M | 282 | 0% | $132.9M | N/A |
#8 | $9.3M | 60 | -37% | N/A | N/A |
#9 | $21.2M | 137 | 12% | N/A | N/A |
#10 | $408.2M | 1646 | 11% | £994.6M | N/A |
What Is Avacta?
Custom antibody alternative, Antibody alternatives, Afinnity reagents Avacta has developed Affimer technology - a revolutionary new engineered affinity protein that is an alternative to antibodies. Affimer molecules have been developed for applications in diagnostics, drug / biomarker discovery, biotech research and development and therapeutics. Find out more on our website.
keywords:N/A
N/A
Total Funding
370
Number of Employees
$57.4M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
Avacta News
CAMBRIDGE & WETHERBY, England--(BUSINESS WIRE)--Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of...
(Alliance News) - Avacta Group PLC said on Wednesday it increased its shareholding in its South Korean joint venture, AffyXell Therapeutics.
Drug developer Avacta Group has announced that a milestone equity payment has been triggered resulting in an increase in the Wetherby-based...
Transformative period for both Diagnostics and Therapeutics Divisions Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, announces its interim resul ...
Avacta announces achievement of pre-clinical development milestone in LG Chem Life Sciences partnership 29-09-2021 Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre| ...
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $195.5M | 370 | 130% | N/A |
#2 | $67.1M | 370 | 65% | N/A |
#3 | $7.5M | 370 | N/A | N/A |
#4 | $83.3M | 370 | 11% | N/A |
#5 | $83.3M | 370 | 2% | N/A |